Effectiveness of prolonged use of fenticonazole in patients with chronic recurrent vulvovaginal candidiasis
Dobrokhotova Yu.E., Borovkova E.I., Burdenko M.V.
Objective: To evaluate the effectiveness of a prolonged course of local therapy with fenticonazole for the prevention of recurrence of vulvovaginal candidiasis in patients with the chronic course of the disease.
Materials and methods: This was a prospective observational study which included 206 patients with recurrent vulvovaginal candidiasis; the patients were divided into two groups. The main group included 96 patients who received the local treatment as follows: fenticonazole 600 mg twice with an interval of 72 hours, then 600 mg once every 10 days for 3 months (subgroup 1, n=36); fenticonazole 600 mg twice with an interval of 72 hours once a month for 3 months (subgroup 2, n=30); fenticonazole 600 mg once every 10 days + 2 courses of platelet-rich plasma therapy (subgroup 3, n=30). The control group included 110 women who received induction therapy with fluconazole 150 mg orally on days 1, 4, 7, and then 150 mg once a week for 3 months. The patients of the groups matched for age, body mass index, somatic and gynecological diseases.
Results: There were no significant differences in the recurrence rate of candida vaginitis in patients who received systemic and topical therapy (p=0.66), but the recurrence rate was significantly higher in the control group during three-month follow-up (p=0.043). The effectiveness of therapy was 94.55% in the control group and there was no recurrence of the disease in 76.36% of patients over the next 3 months. The effectiveness of therapy was 92.71% in the main group and recurrence was not observed in 87.5% of patients.
Conclusion: Topical fenticonazole is effective in relieving and preventing recurrence of vulvovaginal candidiasis. The administration of an induction and prolonged course of fenticonazole may be an acceptable alternative to systemic therapy.
Authors’ contributions: Dobrokhotova Yu.E. – developing the design of the study; Borovkova E.I., Burdenko M.V. – collecting the material, writing the article.
Conflicts of interest: Authors declare lack of the possible conflicts of interests.
Funding: The study was conducted without sponsorship.
Patient Consent for Publication: The patients provided an informed consent for the publication of their data.
Authors’ Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Dobrokhotova Yu.E., Borovkova E.I., Burdenko M.V. Effectiveness of prolonged use of fenticonazole in patients with chronic recurrent vulvovaginal candidiasis.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024 (1): 130-139 (in Russian)
https://dx.doi.org/10.18565/aig.2023.303
Keywords
vulvovaginal candidiasis
candida albicans
chronic recurrent vulvovaginal candidiasis
fluconazole
fenticonazole
platelet-rich plasma
References
- Sobel J.D. Recurrent vulvovaginal candidiasis. Am. J. Obstet. Gynecol. 2016; 214(1): 15-21. https//dx.doi.org/10.1016/j.ajog.2015.06.067.
- Workowski K.A., Bachmann L.H., Chan P.A., Johnston C.M., Muzny C.A., Park I. et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm. Rep. 2021; 70(4): 1-187. https//dx.doi.org/10.15585/mmwr.rr7004a1.
- Nyirjesy P., Brookhart C., Lazenby G., Schwebke J., Sobel J.D. Vulvovaginal candidiasis: a review of the evidence for the 2021 centers for disease control and prevention of sexually transmitted infections treatment guidelines. Clin. Infect. Dis. 2022; 74(Suppl. 2): S162-S168. https//dx.doi.org/10.1093/cid/ciab1057.74: S162.
- Байрамова Г.Р., Савичева А.М., Тапильская Н.И., Иванец Т.Ю., Донников А.Е., Андреев А.О. Эффективность и безопасность применения препарата фентиконазола в терапии неосложненного вульвовагинального кандидоза. Акушерство и гинекология. 2023; 5: 124-31. [Bayramova G.R., Savicheva A.M., Tapilskaya N.I.,Ivanets T.Yu., Donnikov A.E., Andreev A.O. Efficacy and safety of fenticonazole in the treatment of uncomplicated vulvovaginal candidiasis. Obstetrics and Gynecology. 2023; (5): 124-31. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.134.
- Sobel J.D. Vulvovaginal candidosis. Lancet. 2007; 69(9577): 1961-71. https//dx.doi.org/10.1016/S0140-6736(07)60917-9.
- Cooke G., Watson C., Deckx L., Pirotta M., Smith J., van Driel M.L. Treatment for recurrent vulvovaginal candidiasis (thrush). Cochrane Database Syst. Rev. 2022; (1): CD009151. https//dx.doi.org/10.1002/14651858.CD009151.pub2.1: CD009151.
- Edwards A., Rautemaa-Richardson R., Owen C., Nathan B., Palmer B., Wood C. et al.; Saxon Lead Author GDGC. British Association for Sexual Health and HIV national guideline for the management of vulvovaginal candidiasis (2019). Int. J. STD AIDS. 2020; 31: 1124-44. https//dx.doi.org/10.1177/0956462420943034.
- Аполихина И.А., Рамазанова М.О. Лечение кандидозного вульвовагинита локальным клотримазолом: клиническое наблюдение. Акушерство и гинекология. 2022; 9: 155-9. [Apolikhina I.A., Ramazanova M.O. Vulvovaginal candidiasis treatment with local clotrimazole. Obstetrics and Gynecology. 2022; (9): 155-9. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.9.155-159.
- Collins L.M., Moore R., Sobel J.D. Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by candida albicans. J. Low. Genit. Tract Dis. 2020; 24(1): 48-52. https://dx.doi.org/10.1097/LGT.0000000000000496.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации «Урогенитальный кандидоз». 2020. [Ministry of Health of the Russian Federation. Clinical Guidelines “Urogenital Candidiasis”. 2020. (in Russian)].
- Sobel J.D., Wiesenfeld H.C., Martens M., Danna P., Hooton T.M., Rompalo A. et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N. Engl. J. Med. 2004; 351(9): 876-83. https://dx.doi.org/10.1056/NEJMoa033114.
- United States Food and Drug Administration Safety Communication: oral fluconazole in pregnancy. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm497656.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery Accessed April 26, 2016.
- Sanguinetti M., Cantón E., Torelli R., Tumietto F., Espinel-Ingroff A., Posteraro B. In vitro activity of fenticonazole against candida and bacterial vaginitis isolates determined by monoor dual-species testing assays. Antimicrob. Agents Chemother. 2019; 63(7): e02693-18. https://dx.doi.org/10.1128/AAC.02693-18.
- Хашукоева А.З., Агаева З.А., Агаева М.И. Тактика снижения частоты рецидивов вагинального кандидоза у женщин со сниженным иммунитетом. Акушерство и гинекология. 2018; 12: 88-92. [Khashukoeva A.Z., Agaeva Z.A., Agaeva M.I. A strategy to reduce the recurrence rate of vaginal candidiasis in women with weakened immunity. Obstetrics and Gynecology. 2018; (12): 88-92. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.12.88-92.
- Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L. et al. Clinical practice cuideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2015; 62(4): e1-e50. https://dx.doi.org/10.1093/cid/civ933.
- Denning D.W., Kneale M., Sobel J.D., Rautemaa Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect. Dis. 2018 August 2: e339-47. https://dx.doi.org/10.1016/S1473-3099(18)30103-8.
- Sobel J.D. Factors involved in patient choice of oral or vaginal treatment for vulvovaginal candidiasis. Patient Prefer. Adherence. 2013; 8: 31-4. https://dx.doi.org/10.2147/PPA.S8984.
- Martin Lopez J.E. Candidiasis (vulvovaginal). BMJ Clin. Evid. 2015; 2015: 0815.
- Chapple A., Hassell K., Nicholson M., Cantrill J. "You don't really feel you can function normally": women's perceptions and personal management of vaginal thrush". J. Reprod. Infant Psychol. 2000; 18(4): 309-19.https://dx.doi.org/10.1080/713683045.
- Pirotta M., Gunn J., Chondros P., Grover S., O'Malley P., Garland S. Effect of lactobacillus in preventing postantibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ. 2004; 329(7465): 548. https://dx.doi.org/10.1136/bmj.38210.494977.DE.
Received 27.12.2023
Accepted 12.01.2024
About the Authors
Yulia E. Dobrokhotova, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medicine, Pirogov Russian National Research Medical University, Ministry of Health of Russia, pr.dobrohotova@mail.ru, 117997, Russia, Moscow, Ostrovityanov str., 1, https://orcid.org/0000-0002-7830-2290Ekaterina I. Borovkova, Dr. Med. Sci., Associate Professor, Professor, Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University, Ministry of Health of Russia, +7(495)722-63-99, Katyanikitina@mail.ru, 117997, Russia, Moscow, Ostrovityanov str., 1, https://orcid.org/0000-0001-7140-262X
Marina V. Burdenko, PhD, Associate Professor, Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University, Ministry of Health of Russia, +7(495)722-63-99, bmv-0306@rambler.ru, 117997, Russia, Moscow, Ostrovityanov str., 1, https://orcid.org/0000-0002-0304-4901
Similar Articles
